Dr. Elisabeth Wulf

About Dr. Elisabeth Wulf

Elisabeth is a member of our intellectual property and information technology practice within our global transactions group. 

Elisabeth is involved in cross-border corporate transactions and carve-out projects and advises on complex contract negotiation and drafting.

She speaks German, English and French. 

Recent work

• Affimed on a strategic cooperation with Artiva Biotherapeutics for the joint development of a combination therapy in the field of immuno-oncology
• Special Olympics World Games Berlin 2023 Organisationskomitee gGmbH on the World Games and the National Games in advance, both taking place in Berlin on contractual and intellectual property related matters
• Cheplapharm on the acquisition of a product portfolio from Astellas Pharma Inc.
• Novartis on the sale of Novartis Manufacturing GmbH (operating a production plant for biotechnological substances in Marburg) to BioNTech SE
• Catalent on its acquisition of RheinCell Therapeutics
• Scenic Biotech B.V. on a multi-year strategic collaboration with Genentech Inc. regarding genetic modifiers
• Continental on the carve-out of its powertrain business ("Vitesco Technologies")
• The Yokohama Rubber Co., Ltd. on its acquisition of Trelleborg Wheel Systems Holding AB, the wheel systems business of Swedish-listed Trelleborg AB, for an enterprise value of over €2bn
• Flint Group, a global supplier of the printing industry, on the carve out and sale of its XSYS Division
• Boehringer Ingelheim on its sale of rights in the pharmaceutical product Buscopan in Brazil to Hypera
• Hellman & Friedman on its acquisition of the internet platforms AutoScout24, FinanceScout24 und Finanzcheck
• H.I.G. on the carve-out and acquisition of the European polyutherane "system house" business from Covestro
• Mars on the majority stake acquisition in foodspring
• Advent on the acquisition of the methacrylate business from Evonik Industries